PPP2R1A

Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform · P30153 · PPP2R1A on Sugi Atlas →

0 patent compounds predicted against PPP2R1A, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PPP2R1A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis PHASE4COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds PHASE2/PHASE3COMPLETED
Bortezomib in Intrahepatic Cholangiocellular Carcinoma PHASE3UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Open-label Study on Treatment of Primary Aldosteronism With Everolimus PHASE2COMPLETED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer PHASE1/PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120 PHASE1COMPLETED
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Immune Signature of Palmoplantar Pustulosis nanCOMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer nanCOMPLETED
Studying Phosphorus Metabolism nanCOMPLETED
Severe Insulin Resistance in Patients With Type 2 Diabetes nanCOMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure nanRECRUITING
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Study of Metabolic Modifications in Children With Noonan Syndrome nanCOMPLETED
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PPP2R1A binder may also engage these)

ProteinNameSimilarity
Q76MZ3 1.000 Q76MZ3 →
Q32PI5 1.000 Q32PI5 →
P54612 1.000 P54612 →
Q4QQT4 1.000 Q4QQT4 →
Q7TNP2 1.000 Q7TNP2 →
Q38845 1.000 Q38845 →
Q09543 0.998 Q09543 →
Q38951 0.997 Q38951 →
P36179 0.996 P36179 →
P54613 0.996 P54613 →
Q38950 0.995 Q38950 →
P30154 0.995 P30154 →
Q54QR9 0.995 Q54QR9 →
Q9UT08 0.990 Q9UT08 →
P36875 0.986 P36875 →
P31383 0.972 P31383 →
IPO5 Importin-5 0.971 landscape →
Q8BKC5 0.968 Q8BKC5 →
P53620 0.966 P53620 →
Q9I8E6 0.966 Q9I8E6 →
Q9QZE5 0.965 Q9QZE5 →
O60100 0.965 O60100 →
Q9VKY2 0.965 Q9VKY2 →
Q9PUE4 0.965 Q9PUE4 →
Q9QXK3 0.964 Q9QXK3 →
O81742 0.964 O81742 →
O60518 0.964 O60518 →
Q9SUS3 0.964 Q9SUS3 →
P22892 0.963 P22892 →
Q0WW26 0.963 Q0WW26 →